Alterity Therapeutics (ATH) Corporate presentation summary

Company overview and mission

• Focused on developing treatments for neurodegenerative diseases, aiming to slow disease progression and improve patient quality of life.

• Late clinical stage biopharmaceutical company with a differentiated, disease-modifying approach.

Disease background and unmet need

• Multiple System Atrophy (MSA) is a rare, rapidly progressive parkinsonian disorder with no approved treatments and a median survival of 7.5 years after symptom onset.

• MSA affects up to 50,000 patients in the U.S., with over 50% requiring a wheelchair within five years.

• Disease is characterized by motor and autonomic dysfunction, atrophy, and α-synuclein accumulation in multiple brain regions.

Scientific rationale and mechanism of action

• Excess labile iron and α-synuclein aggregation are key drivers of MSA pathology, leading to oxidative injury and neuronal dysfunction.

• ATH434 is an oral, blood-brain barrier-penetrant small molecule that acts as an iron chaperone, reducing excess reactive iron and α-synuclein aggregation.

• The drug preserves neurons and oligodendrocyte function, aiming to modify disease progression.